Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.47 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.47 |
| ▸ | ITGAL | P20701 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132766 | 1.00 | MEN1 (0.54) | MEN1KMT2AMAPTALDH1A1ACHE | |
| SCHEMBL8596084 | 1.00 | MEN1 (0.54) | MEN1KMT2AMAPTALDH1A1ACHE | |
| SCHEMBL9186135 | 0.86 | KMT2A (0.55) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL9186136 | 0.86 | KMT2A (0.55) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL79547 | 0.81 | MEN1 (0.66) | MEN1KMT2AMAPTALDH1A1ACHE | |
| SCHEMBL1598877 | 0.81 | MEN1 (0.66) | MEN1KMT2AMAPTALDH1A1ACHE | |
| SCHEMBL7362683 | 0.81 | MEN1 (0.66) | MEN1KMT2AMAPTALDH1A1ACHE | |
| SCHEMBL6133031 | 0.80 | MEN1 (0.56) | MEN1KMT2AMAPTALDH1A1MAPK1 | |
| SCHEMBL9188705 | 0.80 | KMT2A (0.56) | MEN1KMT2AMAPTALDH1A1HTT | |
| SCHEMBL9188709 | 0.80 | KMT2A (0.56) | MEN1KMT2AMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924278-B2 | Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-03 | — | — | US | disclosed |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-0655060-B1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LTD (GB) | 1998-01-14 | — | — | EP | disclosed |
| US-5700804-A | INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITORS | XENOVA LIMITED (GB) | 1997-12-23 | — | — | US | disclosed |
| EP-0672036-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-09-20 | — | — | EP | disclosed |
| EP-0655060-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994004513-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004512-A1 | PHARMACEUTICALLY ACTIVE DIKETOPIPERAZINES | XENOVA LIMITED (GB) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027121-A1 | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | TAC3, TACR1, SSTR5 | MEN1 1830/4885KMT2A 829/4885MAPT 1892/4885 |
| US-20030114668-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | TACR1, NPSR1, SSTR2 | MEN1 1520/4885KMT2A 1097/4885MAPT 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.